Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taiwan infant co-administration study of Synflorix, Infanrix hexa, and Rotarix
2015-001511-12Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 10-valent pneumococcal conjugate vaccine, pertussis filamentous haemagglutinin and human rotavirus RIX4414 strain vaccine in pneumococcal disease, diphtheria, Tetanus and 5 more, sponsored by GSK. Primary endpoint: Antibody concentrations to pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
02
Drugs
10-valent pneumococcal conjugate vaccinepertussis filamentous haemagglutininhuman rotavirus RIX4414 strain vaccine
03
Conditions
pneumococcal diseasediphtheriaTetanuspertussishepatitis B (HBV)
Beyond the preview
Go deeper on 2015-001511-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001511-12.